Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05319028 · Calithera Biosciences, Inc · PHASE2 · terminated · last registry update 2023-04-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor Decision” | – | Registry record, Calithera Biosciences, Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-10Results posted on the registry: Kronos Bio, Entospletinib + Placebo (NCT05020665)
- 2024-01-10Also stopped (terminated): Kronos Bio, Entospletinib + Placebo (NCT05020665)
- 2023-12-15Results posted on the registry: Washington University School of Medicine, Fostamatinib + Ruxolitinib (NCT04543279)
- 2023-12-15Also stopped (terminated): Washington University School of Medicine, Fostamatinib + Ruxolitinib (NCT04543279)
- 2023-12-11Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib Disodium (NCT02077192)
- 2023-09-18Results posted on the registry: Asana BioSciences, ASN002 (NCT03654755)
- 2023-09-18Also stopped (terminated): Asana BioSciences, ASN002 (NCT03654755)
- 2023-08-08Results posted on the registry: Alexey Danilov, MD, Entospletinib + Obinutuzumab (NCT03010358)
- 2023-05-25Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib disodium + Placebo (NCT03764618)
- 2023-05-09Results posted on the registry: Asana BioSciences, ASN002 + Placebo Oral Tablet (NCT03728504)
- 2023-02-21Also stopped (withdrawn): Portola Pharmaceuticals, Cerdulatinib (NCT04021082)
- 2023-02-06Also stopped (suspended): Ascend Biopharmaceuticals Ltd, ASN-002 (NCT03208296)
- 2022-11-15Results posted on the registry: Asana BioSciences, ASN002 + Placebo Oral Tablet (NCT03531957)
- 2022-10-25Phase 3 first posted: NEAT ID Foundation, Fostamatinib + Placebo (NCT05593770)
- 2022-09-10Phase 3 first posted: Hutchmed, HMPL-523(300mg PO QD) + Placebo (NCT05535933)
- 2022-04-05Results posted on the registry: Alexion Pharmaceuticals, Inc., Cerdulatinib + Rituximab (NCT01994382)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision